Safety and effectiveness of ataluren in patients with Duchenne muscular dystrophy: single-center experience from Saudi Arabia
Objective Duchenne muscular dystrophy (DMD) is a rare X-linked neurodegenerative disorder caused by mutations in the DMD gene. This study examined the efficacy and safety of ataluren, the first oral treatment for DMD with nonsense mutations (nmDMD), in patients in the Middle East. Methods This retro...
Saved in:
| Main Authors: | Mushtaha Ahmad, Alaa ElRasoul, Raneem Sedayou, Mohammed Tamboosi, Hanan Mahroos, Shaimaa Alrashed, Mariam Tunkar, Faisal Alzahrani, Mohammed Alharbi, Mona Aljehani, Mousa Alahmari, Khalid Alqarni, Maha Gashlan, Berna Seker Yilmaz, Nahla M. Alshaikh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-12-01
|
| Series: | Journal of International Medical Research |
| Online Access: | https://doi.org/10.1177/03000605241305252 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The experience of using ataluren in Duchenne muscular dystrophy in Moscow: first results
by: T. N. Kekeeva, et al.
Published: (2024-01-01) -
Assessment of walking in patients with Duchenne muscular dystrophy receiving ataluren in real clinical practice
by: D. V. Aizatulina, et al.
Published: (2025-04-01) -
Opinion of the Italian Association of Myology on Ataluren for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy
by: Luca Bello, et al.
Published: (2025-05-01) -
Dynamics of the course of Duchenne muscular dystrophy in patients taking ataluren and concomitant drug and non-drug therapy
by: V. M. Suslov, et al.
Published: (2024-01-01) -
Ataluren-mediated nonsense variant readthrough in D-bifunctional protein deficiency: A case report
by: Rai-Hseng Hsu, et al.
Published: (2024-12-01)